Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose IV migalastat hydrochloride in healthy volunteers with oral/IV crossover bioavailability arm
NL-OMON40853Phase 1Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Mar 2014
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Started Mar 2014; status: active, not recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON40853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40853.